EUCTR2010-021163-33-ES进行中（未招募）不适用
A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS) - CASPS
The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust0 个研究点目标入组 36 人开始时间: 2012年4月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologically confirmed diagnosis of ASPS
- •2.Age 16 years and older
- •3.Availability of archived tissue blocks or unstained slides to enable confirmation of t(X;17) translocation
- •4.ECOG Performance Status of 0-1
- •5.Life expectancy of >12 weeks
- •6.Progressive disease within 6 months prior to randomisation
- •7.Measurable metastatic disease using RECISTv1.1, i.e. at least one lesion 10 mm in diameter (15 mm in short axis for nodal lesions) assessable by spiral CT (or MRI for brain metastases).
- •8.Patients with brain metastases are permitted provided disease is controlled with a stable dose of corticosteroid and/or non-enzyme inducing anticonvulsant 9.The capacity to understand the patient information sheet and ability to provide written informed consent
- •10.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
- •11.Able to swallow and retain oral medication
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1.Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count ?1.5 x 109/L or platelet count ?100 x 109/L.
- •2.Serum bilirubin ? 1.5 x ULN (unless Gilbert?s syndrome).
- •3.ALT or AST ? 2.5 x ULN. If liver metastases are present, ALT or AST > 5 x ULN.
- •4.Serum creatinine > 1.5 x ULN or a creatinine clearance (calculated or measured) of ? 50mL/min calculated.
- •5.Greater than +1 proteinuria unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio < 1.5.
- •6.History of significant gastrointestinal impairment, as judged by the Investigator,that would significantly affect the absorption of cediranib. 7.Patients with a history of poorly controlled hypertension with resting blood pressure >150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy.
- •8.Any evidence of severe or uncontrolled co-morbidities e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease, or active and uncontrolled infection.
- •9.Evidence of prolonged QTc >480 msec (using Bazetts correction, for which the formula is: QTc = QT/?RR) or history of familial long QT syndrome. 10.Significant recent haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks).
- •11.Major thoracic or abdominal surgery in the 14 days prior to entry into the study, or a surgical incision that is not fully healed.
- •12.Pregnant or breast-feeding women; women of childbearing potential with a positive pregnancy test prior to receiving study medication; women the intention of pregnancy during study treatment; women of child bearing potential unwilling to have a urine or serum pregnancy test prior to study entry (even if surgically sterilised).
- •13.Men and women of childbearing potential unwilling to use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilisation) for the duration of the study and should continue such precautions for 2 weeks after receiving the last study treatment.
- •14.History of anticancer (including investigational, non-registered) treatment in the four weeks prior to first dose of cediranib, with the exception of palliative radiotherapy for symptom control.
- •15.Known hypersensitivity to cediranib or any of its excipients.
- •16.History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within 5 years, unless the patient has been disease free for 2 years and there is a tissue diagnosis of the primary cancer of interest from a target lesion.
- •17.Other concomitant anti-cancer therapy (including LHRH agonists) except steroids.
- •18.Recent history of thrombosis.
- •19.Patients with brain metastases if they are symptomatic requiring increasing steroids in the previous six weeks to study entry or those with evidence of recent and/or active bleeding, or those causing uncontrolled seizures.
研究者
相似试验
招募中
2 期
A trial of cediranib in the treatment of patients with alveolar soft part sarcomaAlveolar soft part sarcomaACTRN12612000020886The Institute of Cancer Research / Royal Marsden Hospital NHS Foundation Trust (UK)36
进行中（未招募）
不适用
A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer - COSAKEUCTR2009-018014-20-GBCommon Services Agency130
招募中
2 期
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusioexcess fluid in the pleural cavityperitoneal cavity fluid10027655NL-OMON35120niversitair Medisch Centrum Sint Radboud32
进行中（未招募）
不适用
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusiosymptomatic malignant ascites or pleural effusionMedDRA version: 12.1Level: LLTClassification code 10025538Term: Malignant ascitesMedDRA version: 12.1Level: LLTClassification code 10026673Term: Malignant pleural effusionEUCTR2010-018275-20-NLniversity Medical Centre Nijmegen St Radboud32
进行中（未招募）
1 期
Clinical trial testing the drug cediranib(AZD2171)against placebo with cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancersbiliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas)MedDRA version: 17.0 Level: LLT Classification code 10004595 Term: Bile duct cancer NOS System Organ Class: 100000004864MedDRA version: 17.0 Level: LLT Classification code 10008594 Term: Cholangiocarcinoma non-resectable System Organ Class: 100000004864MedDRA version: 17.0 Level: LLT Classification code 10017617 Term: Gallbladder cancer non-resectable System Organ Class: 100000004864EUCTR2009-013408-30-GBniversity College London124